Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
J Diabetes Investig ; 14(12): 1378-1382, 2023 Dec.
Article in English | MEDLINE | ID: mdl-37602910

ABSTRACT

The incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are thought to be the main drivers of insulin secretion in individuals with sulfonylurea (SU)-treated KCNJ11 permanent neonatal diabetes. The aim of this study was to assess for the first time the incretin hormone response to carbohydrate and protein/fat in adults with sulfonylurea-treated KCNJ11 permanent neonatal diabetes compared with that of controls without diabetes. Participants were given a breakfast high in carbohydrate and an isocaloric breakfast high in protein/fat on two different mornings. Incremental area under the curve and total area under the curve (0-240 minutes) for total GLP-1 and GIP were compared between groups, using non-parametric statistical methods. Post-meal GLP-1 and GIP secretion were similar in cases and controls, suggesting this process is adenosine triphosphate-sensitive potassium channel-independent. Future research will investigate whether treatments targeting the incretin pathway are effective in individuals with KCNJ11 permanent neonatal diabetes who do not have good glycemic control on sulfonylurea alone.


Subject(s)
Diabetes Mellitus, Type 2 , Diabetes Mellitus , Infant, Newborn , Adult , Humans , Incretins/therapeutic use , Glucagon/metabolism , Insulin/metabolism , Blood Glucose/metabolism , Gastric Inhibitory Polypeptide , Glucagon-Like Peptide 1 , Diabetes Mellitus, Type 2/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...